Clinical Pain Advisor

High Prevalence of Neuropathic Pain After Spinal Cord Injury

Neuropathic pain is highly prevalent after spinal cord injury, with prevalence unrelated to severity of injury.
Independent.ie

Pharma startup Neuropath gets one of Feeney fund's last investments

Chuck Feeney's Atlantic Philanthropies has invested almost $2.5m in Irish pharmaceuticals startup Neuropath Therapeutics. The company aims to develop novel treatments for central nervous system ...
pharmaphorum

Algiax non-opioid drug works in chronic neuropathic pain

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain, another positive development in the search for alternatives to opioids. The phase 2a ...
pharmaphorum

Vertex weakens after neuropathic pain trial reads out

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...
Finanznachrichten

MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / ...
Investing

MIRA begins phase 1 MAD study of Ketamir-2 for neuropathic pain

MIRA begins phase 1 MAD study of Ketamir-2 for neuropathic pain ...